CytomX About Probody Therapeutics Pipeline Partners Investors & News Culture & Careers Conquering Cancer Calls for In the news November 11, 2021 CytomX Therapeutics to Present at Upcoming November Investor Conferences November 4, 2021 CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update November 1, 2021 CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting MORE NEWS CytomX COVID-19 Statement CytomX is committed to the health, safety and well-being of its employees, clinical study participants and others who work with us to develop potentially lifesaving cancer medicines, including staff at our study sites. CytomX continues to closely monitor the COVID-19 pandemic situation and strives to follow and have its employees follow appropriate local, state and federal guidelines. In March 2020, we initiated a mandatory work from home protocol for all employees whose work could be conducted from home, with minimal onsite laboratory operations. Laboratory and other company operations have gradually increased over time with onsite employees required to follow our prescribed safety precautions. We continue to allow employees whose work can be conducted from home to work from home. In November 2021, CytomX initiated a vaccination policy which requires any employee coming on CytomX premises to be vaccinated for COVID-19, unless they qualify for accommodation due to a medical reason, or because of a sincerely held religious belief. Visitors and contractors who come on site are required to register before entering and to answer basic health questions and check for fever prior to entry. The measures we take from time to time during the pandemic may change and we disclaim any obligation to update this statement. Contact Us 151 Oyster Point Blvd, Suite 400 South San Francisco, CA 94080-1913 Offices: 650-515-3185 Fax: 650-351-0353 Share Linkedin Twitter © 2021 CytomX Therapeutics, Inc. | PROBODY, CYTOMX, and our corporate logo are U.S. registered trademarks of CytomX Therapeutics, Inc. IHZ is a trademark of CytomX Therapeutics, Inc. All other brands and trademarks referenced herein are the property of their respective owners. About Overview Vision & Mission Our Values Executive Team Board of Directors Scientific Advisory Board Contact Us Probody Therapeutics Our Probody Approach How Probody Therapeutics Work A Versatile Platform Scientific Publications & Presentations Pipeline Advancing a Pipeline Lead Candidates Clinical Trials Access for HCPs/Patients Partners Opportunities Current Partners Investors & News Corporate Profile Press Releases Events & Presentations Scientific Publications Corporate Governance Stock Information Financial & Filings Analyst Coverage Investor Resources Culture & Careers Overview Xtraordinary Culture Current Openings Total Rewards Program Corporate Amenities Home Terms of use Privacy policy Disclaimer for Twitter